You will see this name on forums soon, attached to claims. There is nothing behind it yet.
On 29 September 2026, Novo Nordisk and Hengrui Pharma announced a licence agreement for HRS-1596. Both companies describe it as a GLP-1 and GIP dual receptor agonist with potential for once-weekly oral dosing.12
Novo has agreed to pay $300 million up front, with development, regulatory and commercial milestones that could bring the total to up to $2.6 billion, plus royalties on net sales in the licensed territory. Novo would get exclusive rights to develop, manufacture and commercialise it everywhere except the Chinese mainland, the Hong Kong SAR, the Macao SAR and Taiwan Region, where Hengrui keeps them.2
None of that has happened yet. The agreement is subject to clearance under the US Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, and is expected to close in the fourth quarter of 2026.12
The phrase doing the most work in the announcements is phase 1-ready. The drug has not started phase 1. Hengrui says it has approval in China to begin those trials, for weight management and type 2 diabetes, which is what ready means here.2 No human results have been published.
Its structure has not been disclosed, so it is not public knowledge whether HRS-1596 is a peptide at all. Nobody outside the two companies can make it, which means nobody can sell you any.
What is actually known
Three things. All three come from the companies, not from data.
What it is said to act on. The GLP-1 receptor and the GIP receptor, the same two targets as tirzepatide.1 Hengrui says it is designed to reduce weight and improve blood sugar control through appetite suppression, insulin secretion and improved insulin sensitivity.2 None of that has been shown in a published study.
How it is meant to be taken. A pill, once a week. Both companies describe this as potential rather than demonstrated.12
Where it is in development. Phase 1-ready. Hengrui has regulatory approval in China to start phase 1 trials and has not started them.2 Everything known about the compound comes from laboratory and animal work that has not been published.
What is not known
Four things, and the list is longer than the one above.
Whether it is a peptide. Neither company disclosed the structure. A GLP-1 and GIP dual agonist can be a peptide, as tirzepatide is, or a small molecule, as orforglipron is for GLP-1 alone. Which one this is has not been stated publicly, and it determines almost everything about how it would be made and copied.
How it achieves once-weekly oral dosing. Neither company disclosed the formulation approach either. This is the hard part of the whole proposition and the part they have said least about.
The closest thing to a hint is Novo's research chief describing the company as having pioneered the field of oral peptides and wanting to advance its oral pipeline.2 That is a statement about Novo rather than about this molecule, and it is not confirmation of anything.
Whether it works. There is no effect size. No weight loss figure, no A1C figure, no safety data in people. An agreement is a bet on a drug, not evidence about it.
Whether it will reach anyone. Most compounds that enter phase 1 do not reach market. A drug that has not yet entered phase 1 is several years and several failure points away from a pharmacy.
Can you buy it?
No, and this is the part that matters if you are reading this on a forum.
HRS-1596 appears in none of the listings we track, across every seller in our capture.3
There is a straightforward reason. Nobody outside Novo and Hengrui can make HRS-1596, because its structure has not been disclosed. A supplier cannot synthesise a molecule it cannot identify, and no amount of demand changes that.
So if you see it offered, you are not being sold HRS-1596. You are being sold something else with that name on the label, which is a problem this site documents elsewhere: our decoder guide covers how often a name on a vial is not what is in it.
It is not in our compound library and no seller we track lists it, both checked against our data rather than assumed. Three things would change that: human data from a trial, a published structure, or sellers listing it. Any one of those makes it something readers can encounter rather than a line in a press release.
Why a weekly pill would matter
Because the two oral GLP-1 drugs that exist are both daily, and one of them is difficult to take.
Oral semaglutide, sold as the Wegovy pill, has to be swallowed on an empty stomach with a small sip of water, and nothing else for at least half an hour. Foundayo, the orforglipron pill approved in April, has no food or water restrictions. Both are once daily.
A weekly pill would remove the daily routine entirely, and forgetting doses is the single most common reason people stop taking a medicine. It would also sit between the two formats you currently choose between: a weekly injection with a needle, or a daily pill without one.
Our comparison of the two existing pills covers how they differ, and our comparison of the weekly injectables covers what the needle versions achieve.
Why oral delivery is hard here
This is why it is a bet worth up to $2.6 billion and not an engineering job.
Peptides are destroyed by digestion. That is the central problem, and it is why the GLP-1 drugs you know are injected. Oral semaglutide solves it with an absorption enhancer and strict dosing conditions, which is where the empty stomach rule comes from, and even then only a small fraction is absorbed.
Orforglipron avoids the problem by not being a peptide. It is a small molecule, which is why it has no food restrictions.
So the two routes to an oral drug in this class are a peptide with heavy formulation around it, or a non-peptide that acts on the same receptor. A once-weekly oral version requires solving absorption and then keeping the drug in the body for seven days, which nobody has done in this class by any route except injection.
That is why the undisclosed structure matters. It is the difference between two very different engineering problems, and the companies have not said which one they are solving.
Common questions
What is HRS-1596?
An experimental drug that Novo Nordisk has agreed to license from Hengrui Pharma, announced on 29 September 2026 and not yet closed. Both companies describe it as a GLP-1 and GIP dual receptor agonist with potential for once-weekly oral dosing. It has not been tested in people.
Is HRS-1596 a peptide?
Unknown. Neither company has disclosed its structure. A GLP-1 and GIP dual agonist can be a peptide like tirzepatide or a small molecule, and which one this is has not been made public.
How much is Novo paying?
$300 million up front, with development, regulatory and commercial milestones that could bring the total to up to $2.6 billion, plus royalties on net sales in the licensed territory. The agreement has not closed: it needs US antitrust clearance and is expected to complete in the fourth quarter of 2026. Hengrui keeps the rights in the Chinese mainland, the Hong Kong SAR, the Macao SAR and Taiwan Region.
When will it be available?
Not for years, if at all. It is described as phase 1-ready: Hengrui has approval in China to begin phase 1 trials and has not begun them. Most compounds entering phase 1 never reach market.
How much weight does it cause people to lose?
Nobody knows. No human trial has been run and no human results have been published, so there is no effect size of any kind, and anyone quoting one is inventing it.
Can you buy HRS-1596?
No. It appears in none of the listings we track. Nobody outside Novo and Hengrui can make it, because its structure has not been disclosed, and a supplier cannot synthesise a molecule it cannot identify.
Is a weekly pill better than a weekly injection?
Unknown, and it depends what you value. The existing oral GLP-1 drugs are both daily, and one requires an empty stomach. A weekly pill would remove both the needle and the daily routine, but nothing has shown it can match an injection for effect.
Sources
- Novo Nordisk. Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596. Bagsværd, 29 September 2026. novonordisk.com. Company announcement. Describes HRS-1596 as a phase 1-ready glucagon-like peptide-1 receptor and gastric inhibitory polypeptide receptor dual agonist with potential for once-weekly oral administration. Total potential deal value up to 2.6 billion US dollars, including a 300 million dollar upfront payment, plus potential sales royalties. The agreement is subject to clearance under the US Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions, and the transaction is expected to close in the fourth quarter of 2026.
- Hengrui Pharma. Hengrui Pharma and Novo enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596. Shanghai, 29 September 2026, via PR Newswire. prnewswire.com. Company announcement, read in full. Novo obtains exclusive rights to develop, manufacture and commercialise HRS-1596 globally, excluding the Chinese mainland, the Hong Kong SAR, the Macao SAR and Taiwan Region. Total potential value up to 2.6 billion US dollars contingent on development, regulatory and commercial milestones, including a 300 million dollar upfront payment, with Hengrui eligible for royalties on net sales within the licensed territory. States that HRS-1596 is designed to reduce weight and improve glycaemic control through multiple mechanisms including appetite suppression, stimulation of insulin secretion and improved insulin sensitivity, and that Hengrui has received approval in China to initiate phase I clinical trials for weight management and type 2 diabetes. Quotes Martin Holst Lange of Novo describing the company as having pioneered the field of oral peptides. The announcement does not disclose the compound's structure or the formulation approach intended to enable once-weekly oral dosing, and no human trial results accompanied it. The agreement is subject to US Hart-Scott-Rodino clearance and other customary closing conditions, expected to close in the fourth quarter of 2026.
- Peptide Decoding compound library and vendor price capture, 29 September 2026. peptidedecoding.com/prices. Our own data, both checked rather than assumed. HRS-1596 appears in zero listings across every seller tracked, and is not in our compound library.
Citing this page. Peptide Decoding. Novo Has Agreed to Pay $300 Million for a Pill Nobody Has Taken. Deal terms from the companies' announcements of 29 September 2026. https://peptidedecoding.com/news/hrs-1596-novo-hengrui